Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab in Recurrent NSCLC
NCT00063388Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2003
- Primary completion
- Jun 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoint: Tumor Response Rate in EGFR-positive subjects. Started May 2003; status: completed.
02
Drugs
KL-140
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00063388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063388.